Repository logo
 
Publication

Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis

dc.contributor.authorMartins, Diana Mafalda Miranda
dc.contributor.authorMatos, Cristiano
dc.contributor.authorJoaquim, João José Morais, 1969-
dc.date.accessioned2016-11-21T12:09:39Z
dc.date.available2016-11-21T12:09:39Z
dc.date.issued2015
dc.date.updated2016-10-20T21:58:20Z
dc.description.abstractMultiple Sclerosis (MS) is a chronic, autoimmune, neurodegenerative and demyelinating disease of the central nervous system, which affects the quality of life of patients and their families. This disease is characterized by relapses or exacerbations, which are clinical consequences of increased inflammatory activity in the CNS. Few treatment options for patients with secondary progressive multiple sclerosis (SPMS) is available. Mitoxantrone (type II topoisomerase inhibitor) could be used to treat MS, most notably the subset known as SPMS. Mitoxantrone will not cure MS, but could be effective in slowing the progression of SPMS and extending the time between relapses in relapsing-remitting MS and progressive relapsing MS.pt_PT
dc.identifier.citationMartins, Diana Mafalda Miranda; Matos, Cristiano; Joaquim, João José. Mitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosis, Trabalho apresentado em 15th ISoP Annual Meeting ‘‘Cubism in Pharmacovigilance’’ , In 15th ISoP Annual Meeting ‘‘Cubism in Pharmacovigilance’’ - Abstracts, Praga, 2015.pt_PT
dc.identifier.doiDOI 10.1007/s40264-015-0346-0pt_PT
dc.identifier.issn1179-1942
dc.identifier.urihttp://hdl.handle.net/10400.26/15532
dc.language.isoporpt_PT
dc.peerreviewedyespt_PT
dc.publisherSpringer Internationalpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/pt_PT
dc.subjectMitoxantronapt_PT
dc.subjectCardiotoxicidadept_PT
dc.subjectEsclerose múltiplapt_PT
dc.subjectTerapêuticapt_PT
dc.subjectFarmáciapt_PT
dc.titleMitoxantrone treatment-induced cardiotoxicity in patients with multiple sclerosispt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleDrug safetypt_PT
oaire.citation.volume38pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Diana Martins [ISoP 2015_Drug Safety].pdf
Size:
144.06 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.85 KB
Format:
Item-specific license agreed upon to submission
Description: